Pakistan Form-6A: Class A Enlistment Application for Imported Devices

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Imported Class A devices in Pakistan follow the enlistment route and use the Form-6A application. The applicant must be an importer holding a valid Establishment Licence (acting in the capacity of an authorised representative), and must attach the fee prescribed under rule 63 together with the particulars, documents or samples required by Form-6A. The format of Form-6A was amended in 2022 through S.R.O. 430(I)/2022, and the current version must be used at submission. Three points follow from this opening position. Eligibility is licence-based, so the entity milestone discussed elsewhere in this series sits in front of every Class A filing. Completeness is checked at intake under a rule that applies to every route, whatever the risk class. And form version control is a live failure point that has already been settled by a 2022 amendment — meaning any filing prepared on a stored, pre-amendment copy of the form is out of compliance before DRAP reads a single line of it.

  • Class A goes through enlistment, a distinct statutory route with its own form, Form-6A, not a simplified variant of the registration track.
  • Only an importer holding a valid Establishment Licence, acting as authorised representative, may file the Form-6A application.
  • The application must carry the rule 63 fee plus the particulars, documents or samples listed in Form-6A; incomplete applications can be returned.
  • Form-6A was amended by S.R.O. 430(I)/2022 in 2022 — filing an outdated version is a rejection risk that is entirely avoidable by checking the portal before submission.

2. Legal basis

The enlistment route, the form used for imported Class A devices, the completeness and fee requirements, and the amendment history of Form-6A are all traceable to the Medical Devices Rules, 2017 and the 2022 statutory regulatory order. The fee amounts in the table are drawn from registration practice compilation and should always be confirmed against the current Schedule C before payment.

ItemLegal sourceProvision
Class A follows enlistmentMedical Devices Rules, 2017 (notified 2018-01-16)Rule 13(1)(a)
Imported Class A uses Form-6ASame instrumentRule 14(2)(a)
Fee and particulars must be attachedSame instrumentRule 14(3)
Unpaid fees or incomplete materials may be returnedSame instrumentRule 14(4)
Amendment of Form-6AS.R.O. 430(I)/2022 (March 2022)Amends Form 6A and Form 7A
Enlistment fee (imported Class A)MDR 2017 Schedule C (rule 63): PKR 5,000 / renewal PKR 5,000Registration practice compilation; the current Schedule C governs

3. Expert insights

Insight one: enlistment for Class A is an independent statutory type, not a simplified registration. Rule 13(1) places it alongside the registration track for B/C/D, each with its own corresponding form (Form-6A versus Form-7A). In the text of the rules the two are parallel institutions, not two tiers of the same system. This distinction matters when advising clients: describing Class A enlistment as a light registration understates the discipline the intake rules actually impose on the filing. It also matters for portfolio planning, because a sponsor cannot assume that lessons, templates or fee assumptions carried over from a registration project will transfer unchanged to an enlistment project — the forms differ, the fee categories differ, and the terminology used on the portal differs as well.

Insight two: the enlistment route is also subject to the completeness check. Rule 14(3)–(4) applies to both routes alike: where fees are unpaid or materials are incomplete, the MDB may return the application directly. So low risk does not mean low requirements. The intake gate is mechanical and unforgiving — it reads the fee receipt and the attachment list, not the risk class of the device. Sponsors who treat Class A casually because the device is low-risk are the ones who meet Rule 14(4) in the worst way, through a returned application.

Insight three: form version is the most common return point in practice. Form-6A was amended in 2022. Applications filed on the old version of the form are treated as non-compliant with the format requirements, and since the paper submission channel ceased to be accepted from 21 July 2025, version checking must be completed before submission — there is no offline fallback in which an old form can be quietly corrected. The check takes minutes on the DRAP portal; the cost of skipping it is an entire filing cycle. The lesson generalises: every DRAP form used in a Pakistan project should be pulled fresh from the portal at filing time, never from a local archive, because the portal is the single authoritative source of what the authority will accept.

4. Practical recommendations

GRZAN follows a fixed three-step discipline before any Form-6A goes out, precisely because the return reasons at this stage are administrative rather than scientific.

  • First, obtain the current version of the form and the checklist from the local partner’s DRAP portal account, so the filing is built on the live template rather than a stored copy.
  • Second, tick every item on the checklist one by one and retain the record, so completeness is demonstrated before submission rather than discovered after a return.
  • Third, confirm the fee amount matches the enlistment category — enlistment and registration fees differ (see the fees guidance), and a misrouted payment is itself a return trigger.
  • Only after all three steps are complete is the application formally submitted — because once formally submitted and paid, the draft is locked as a non-editable version.
  • Keep the manufacturer authorisation from the country of origin notarised, and attach either a notarised FSC or a notarised DoC, as the checklist requires.

5. Verification checklist

  • □ The current version of Form-6A has been adopted
  • □ The applicant’s Establishment Licence is valid
  • □ The manufacturer authorisation notarised in the country of origin has been attached
  • □ A notarised FSC or a notarised DoC has been attached (either one)
  • □ The fee amount matches the enlistment category
  • □ The portal completeness check has been completed before formal submission

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Pakistan. Our team prepares dossiers to DRAP expectations, manages eCTD-format submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail